AB5200
Anti-Potassium Channel GIRK2 Antibody
Chemicon®, from rabbit
Synonym(s):
G-protein Activated Inwardly Rectifying Potassium Channel
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
mouse, rat
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... KCNJ6(3763)
Related Categories
Specificity
Recognizes a full length Kir3.2 (GIRK2, G-protein Activated Inwardly Rectifying Potassium Channel 2). Does not cross react with any other potassium channel antigens tested so far.
Immunogen
GST fusion protein from the C-terminal portion of mouse GIRK2 protein (amino acids 374-414) (Accession P48542).
Application
Anti-Potassium Channel GIRK2 Antibody detects level of Potassium Channel GIRK2 & has been published & validated for use in IH & WB.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Ion Channels & Transporters
Ion Channels & Transporters
Western blot: 1:200 using ECL on rat brain membranes.
Immunohistochemistry on rat brain sections.
Dilutions should be made using a carrier protein such as BSA (1-3%)
Optimal working dilutions must be determined by the end user.
Immunohistochemistry on rat brain sections.
Dilutions should be made using a carrier protein such as BSA (1-3%)
Optimal working dilutions must be determined by the end user.
Physical form
Affinity purified immunoglobulin. Lyophilized from phosphate buffered saline, pH 7.4, containing 1% BSA, 5% sucrose as a stabilizer and 0.025% sodium azide as a preservative. Reconstitute with 200 μL of sterile deionized water. Centrifuge antibody preparation before use (10,000 xg for 5 min).
Storage and Stability
Maintain lyophilized material at -20°C for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles
Analysis Note
Control
CONTROL ANTIGEN: Included free of charge with the antibody is 120 μg of control antigen (lyophilized powder). The stock solution of the antigen can be made up using 100 μL of PBS. For positive control, in Western blot use 20 ng of protein per minigel lane. For negative control, preincubate 3 μg of fusion protein with 1 μg of antibody for one hour at room temperature. Optimal concentrations must be determined by the end user.
CONTROL ANTIGEN: Included free of charge with the antibody is 120 μg of control antigen (lyophilized powder). The stock solution of the antigen can be made up using 100 μL of PBS. For positive control, in Western blot use 20 ng of protein per minigel lane. For negative control, preincubate 3 μg of fusion protein with 1 μg of antibody for one hour at room temperature. Optimal concentrations must be determined by the end user.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Hazard Statements
Precautionary Statements
Hazard Classifications
Aquatic Chronic 3
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
PDSCL
Poisonous substance
JAN Code
AB5200-200UL:
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tammy Ryan et al.
Nature communications, 9(1), 817-817 (2018-02-28)
Neuronal loss in Parkinson's disease (PD) is associated with aberrant mitochondrial function and impaired proteostasis. Identifying the mechanisms that link these pathologies is critical to furthering our understanding of PD pathogenesis. Using human pluripotent stem cells (hPSCs) that allow comparison
Andrzej Swistowski et al.
Current protocols in stem cell biology, Chapter 2, Unit2D-Unit2D (2012-08-09)
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are potentially an unlimited cell source for cell replacement therapy and personalized medicine. Before hESC- and iPSC-based therapy can be moved from bench to bedside, however, it is essential
Andrzej Swistowski et al.
PloS one, 4(7), e6233-e6233 (2009-07-15)
Human embryonic stem cells (hESCs) may provide an invaluable resource for regenerative medicine. To move hESCs towards the clinic it is important that cells with therapeutic potential be reproducibly generated under completely defined conditions. Here we report a four-step scalable
Adolfo López-Ornelas et al.
Cells, 12(23) (2023-12-09)
Human embryonic stem cells (hESCs) differentiate into specialized cells, including midbrain dopaminergic neurons (DANs), and Non-human primates (NHPs) injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine develop some alterations observed in Parkinson's disease (PD) patients. Here, we obtained well-characterized DANs from hESCs and transplanted them
Fahad Mubariz et al.
Frontiers in neuroscience, 17, 1152503-1152503 (2023-06-19)
Mutations in the GBA1 gene are the single most frequent genetic risk factor for Parkinson's disease (PD). Neurodegenerative changes in GBA1-associated PD have been linked to the defective lysosomal clearance of autophagic substrates and aggregate-prone proteins. To elucidate novel mechanisms
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service